Safety and efficacy of intravenous ultra-high dose methylcobalamin treatment for peripheral neuropathy: A phase I/II open label clinical trial

Internal Medicine

Volumn 53, Issue 17, 2014, Pages 1927-1931

  Shibuya, Kazumoto ^a   Misawa, Sonoko ^a   Nasu, Saiko ^a   Sekiguchi, Yukari ^a   Beppu, Minako ^a   Iwai, Yuta ^a   Mitsuma, Satsuki ^a   Isose, Sagiri ^a   Arimura, Kimiyoshi ^b   Kaji, Ryuji ^c   Kuwabara, Satoshi ^a  

^a CHIBA UNIVERSITY   (Japan)

^b Okatsu Neurology and Rehabilitation Hospital   (Japan)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Axonal regeneration; Methylcobalamin; Peripheral neuropathy

Indexed keywords

CYANOCOBALAMIN; MECOBALAMIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EXAMINATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; MALE; MUSCLE STRENGTH; NERVE FIBER DEGENERATION; PERIPHERAL NEUROPATHY; PROSPECTIVE STUDY; QUANTITATIVE ASSAY; RESPIRATORY TRACT INFECTION; SEBORRHEIC DERMATITIS; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; INNERVATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; NERVE FIBER; NERVE REGENERATION; PATHOLOGY; PERIPHERAL NERVOUS SYSTEM DISEASES; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SKELETAL MUSCLE; TIME;

ADULT; AGED; AXONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; NERVE REGENERATION; PERIPHERAL NERVOUS SYSTEM DISEASES; TIME FACTORS; TREATMENT OUTCOME; VITAMIN B 12;

EID: 84906839436     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.53.1951     Document Type: Article

References (26)

1. Hoke A. Mechanisms of disease: what factors limit the success of peripheral nerve regeneration in humans? Nat Clin Pract Neurol 2: 448-454, 2006.
2. Yuki N, Hartung HP. Guillain-Barré syndrome. N Engl J Med 366: 2294-2304, 2012.
3. Kuwabara S, Misawa S, Mori M, Tamura N, Kubota M, Hattori T. Long term prognosis of chronic inflammatory demyelinating polyneuropathy: a five year follow up of 38 cases. J Neurol Neurosurg Psychiatry 77: 66-70, 2006.
4. Watanabe T, Kaji R, Oka N, Bara W, Kimura J. Ultra-high dose methylcobalamin promotes nerve regeneration in experimental acrylamide neuropathy. J Neurol Sci 122: 140-143, 1994.
5. Okada K, Tanaka H, Temporin K, et al. Methylcobalamin increases Erk1/2 and Akt activities through the methylation cycle and promotes nerve regeneration in a rat sciatic nerve injury model. Exp Neurol 222: 191-203, 2010.
6. Yamazaki K, Oda K, Endo C, Kikuchi T, Wakabayashi T. Methylcobalamin (methyl-B12) promotes regeneration of motor nerve terminals degenerating in anterior gracile muscle of gracile axonal dystrophy (GAD) mutant mouse. Neurosci Lett 170: 195-197, 1994.
7. Akaike A, Tamura Y, Sato Y, Yokota T. Protective effects of a vitamin B12 analog, methylcobalamin, against glutamate cytotoxicity in cultured cortical neurons. Eur J Pharmacol 241: 1-6, 1993.
8. Zhang YF, Ning G. Mecobalamin. Expert Opin Investig Drugs 17: 953-964, 2008.
9. Kaji R, Kodama M, Imamura A, et al. Effect of ultrahighdose methylcobalamin on compound muscle action potentials in amyotrophic lateral sclerosis: a double-blind controlled study. Muscle Nerve 21: 1775-1778, 1998.
10. Kleyweg RP, van der Meche FG, Schmitz PI. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle Nerve 14: 1103-1109, 1991.
11. Compston A. Aids to the investigation of peripheral nerve injuries. Medical Research Council: Nerve Injuries Research Committee. His Majesty’s Stationery Office: 1942; pp. 48 (iii) and 74 figures and 7 diagrams; with aids to the examination of the peripheral nervous system. By Michael O’Brien for the Guarantors of Brain. Saunders Elsevier: 2010; pp. [8] 64 and 94 Figures. Brain 133: 2838-2844, 2010.
12. Fan E, Ciesla ND, Truong AD, Bhoopathi V, Zeger SL, Needham DM. Inter-rater reliability of manual muscle strength testing in ICU survivors and simulated patients. Intensive Care Med 36: 1038-1043, 2010.
13. Kohara N, Kimura J, Kaji R, et al. F-wave latency serves as the most reproducible measure in nerve conduction studies of diabetic polyneuropathy: multicentre analysis in healthy subjects and patients with diabetic polyneuropathy. Diabetologia 43: 915-921, 2000.
14. Graham RC, Hughes RA. A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale. J Neurol Neurosurg Psychiatry 77: 973-976, 2006.
15. Kuwabara S, Nakazawa R, Azuma N, et al. Intravenous methylcobalamin treatment for uremic and diabetic neuropathy in chronic hemodialysis patients. Intern Med 38: 472-475, 1999.
16. Yamatsu K, Yamanishi Y, Kaneko T, Ohkawa I. Pharmacological studies on degeneration and regeneration of the peripheral nerves. (2) Effects of methylcobalamin on mitosis of Schwann cells and incorporation of labeled amino acid into protein fractions of crushed sciatic nerve in rats. Nihon Yakurigaku Zasshi (Folia Pharmacologica Japonica) 72: 269-278, 1976 (in Japanese, Abstract in English).
17. Bunge RP, Bunge MB, Eldridge CF. Linkage between axonal ensheathment and basal lamina production by Schwann cells. Annu Rev Neurosci 9: 305-328, 1986.
18. Cornbrooks CJ, Carey DJ, McDonald JA, Timpl R, Bunge RP. In vivo and in vitro observations on laminin production by Schwann cells. Proc Natl Acad Sci USA 80: 3850-3854, 1983.
19. Ard MD, Bunge RP, Bunge MB. Comparison of the Schwann cell surface and Schwann cell extracellular matrix as promoters of neurite growth. J Neurocytol 16: 539-555, 1987.
20. Sereda MW, Meyer zu Horste G, Suter U, Uzma N, Nave KA. Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat Med 9: 1533-1537, 2003.
21. Pareyson D, Reilly MM, Schenone A, et al. Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMTTRAUK): a double-blind randomised trial. Lancet Neurol 10: 320-328, 2011.
22. d’Ydewalle C, Benoy V, Van Den Bosch L. Charcot-Marie-Tooth disease: emerging mechanisms and therapies. Int J Biochem Cell Biol 44: 1299-1304, 2012.
23. Rivieccio MA, Brochier C, Willis DE, et al. HDAC6 is a target for protection and regeneration following injury in the nervous system. Proc Natl Acad Sci USA 106: 19599-19604, 2009.
24. Verhamme C, deHaan RJ, Vermeulen M, Baas F, deVisser M, vanSchaik IN. Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial. BMC Med 7: 70, 2009.
25. Burns J, Ouvrier RA, Yiu EM, et al. Ascorbic acid for Charcot Marie-Tooth disease type 1A in children: a randomised, doubleblind, placebo-controlled, safety and efficacy trial. Lancet Neurol 8: 537-544, 2009.
26. Micallef J, Attarian S, Dubourg O, et al. Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 8: 1103-1110, 2009.